erlotinib hydrochloride has been researched along with Esophagitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Hui, Z; Liang, J; Lv, J; Wang, J; Wang, L; Wang, X; Zhai, Y; Zhu, H; Zou, S | 1 |
| Blackstock, AW; Decker, RH; Gettinger, SN; Khandani, A; Lankford, S; Moore, DT; Morris, DE; Petty, WJ; Schwartz, G; Socinski, MA; Stinchcombe, TE | 1 |
3 trial(s) available for erlotinib hydrochloride and Esophagitis
| Article | Year |
|---|---|
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagitis; Exanthema; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Survival Rate | 2013 |
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Esophagitis; Esophagus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy, Conformal; Remission Induction; Tracheoesophageal Fistula; Treatment Failure | 2012 |